Autopsy report · NCT03985423
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Registered 1 year before it started.
- Ran for about 1 year 1 month before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 2 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Swedish Orphan Biovitrum
- Sponsor type
- Industry
- Conditions
- Hemophagocytic Lymphohistiocytoses
- Interventions
- Emapalumab-Lzsg
- Participants
- 7
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.